noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

ImmuCell Corporation

2025 Form 10-K (proofs 0000811641 118730 ALL DOCS clean pn120)
ImmuCell Corporation

Corporate Presentation (Investor Relations April 2026 Final)
Peakequity Partners Management Co LLC

PeakEquity Partners Successfully Exits G5

Environment

Pappas Capital LLC

07/17/2025 | Press release | Archived content

Minoryx receives a EUR 26.9m grant within the framework of the Eu...

News | 07. 17. 2025

Minoryx

Barcelona, Spain, 17 July 2025 - Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders today announces that it has secured a EUR 26.9m non-dilutive grant for the development of its LERI4CNS project, which will validate leriglitazone for treating potentially lethal rare diseases affecting the CNS. The grant was given as part of the pan-European project "Important Project of Common European Interest ('IPCEI') Med4Cure", of which Minoryx Therapeutics is an Associated Member.

Pappas Capital LLC published this content on July 17, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 09:57 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format